
Search
Filter Results
Displaying 291–300 of 906 results
-
Oct 20, 2021
Opus Genetics Announces Two Key Leadership Appointments
Dr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Oct 18, 2021
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
The emerging gene therapy is being designed to more safely reach the fovea
-
Oct 15, 2021
Learning to Fall After Vision Loss
When Justin’s vision loss progressed quickly due to retinitis pigmentosa at 25 years old, he thought skateboarding wouldn’t be possible anymore. Ten years later, with the help of his white cane and audio devices, Justin is now working to enhance accessibility in skateboarding for the blind and visually impaired community.
-
Oct 13, 2021
Foundation Fighting Blindness Appoints Richele Donat, SPHR, as Chief Human Resources Officer
Ms. Donat brings over twenty years of successful human resource leadership experience to the Foundation executive team
-
Oct 8, 2021
Foundation Hosts Workshop on USH1B Research and Therapy Development
Emerging dual-vector gene therapies to address current cargo-size limitations were highlighted during the meeting.
-
Oct 7, 2021
Covid Revealed What Science Can Do When Funding is Found
‘In some ways, the pandemic ought to make us all feel more upbeat about the long-term future of medical research.’
-
Oct 4, 2021
RD Fund Appoints Tony Adamis, MD to Board of Directors
The RD Fund announces the appointment of Anthony (Tony) Adamis, MD, to its board of directors.
-
Sep 30, 2021
The emerging treatment targets a specific mutation (c.2991+1655A>G in Intron 26) of the gene CEP290 which causes Leber congenital amaurosis 10 (LCA 10)
-
Sep 28, 2021
RD Fund Launches Opus Genetics to Advance Gene Therapies for Inherited Retinal Diseases
First two programs are for Leber congenital amaurosis: LCA5-lebercillin and LCA13-RDH12
-
Funded Foundation Fighting Blindness Grants and Awards for Fiscal Year 2021 (July 1, 2020–June 30, 2021)